Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on octreotide or cabergoline during stable pegvisomant therapy in acromegaly
2007-005585-12Phase 4Completed
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Nov 2007
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of octreotide, cabergoline and pegvisomant in acromegaly (2 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Change in endogenous growth hormone levels. Started Nov 2007; status: completed.
02
Drugs
octreotidecabergolinepegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2007-005585-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005585-12.